Latest Content

After cancer, even your closet tells a story you never imagined living. One quiet afternoon, that story took a hilarious and unexpected turn.

Real-world treatment with Yescarta demonstrated durable responses and manageable safety in patients with relapsed/refractory follicular lymphoma.

Dexamethasone before Yescarta reduced the severity of ICANS but did not change how often ICANS or CRS occurred in patients with LBCL.

Pelabresib plus Jakafi delivered stronger, clinically meaningful benefits versus Jakafi alone for people with untreated myelofibrosis.

Tecvayli plus Darzalex Faspro improved overall and progression-free survival versus standard daratumumab regimens in relapsed/refractory multiple myeloma.

Jaypirca therapy improved progression-free survival versus bendamustine plus Rituxan a phase 3 trial for untreated CLL/SLL.

In a recent interview with CURE, Dr. Kai Tsao discussed treatment advancements for patients with prostate cancer.

Lore Gruenbaum, chief scientific officer of Blood Cancer United, sat down for an interview with CURE to discuss the themes shaping blood cancer care today.

Dr. Josh Brody discussed key clinical trial findings for patients with diffuse large B-cell lymphoma.

In a direct comparison, Jaypirca matched Imbruvica in response and suggested a progression-free survival benefit for patients with CLL/SLL.

Dr. Robert Orlowski says a single-drug option in newly diagnosed myeloma may offer strong responses with fewer side effects and preserve future treatments.

A clinical trial found that Jaypirca was more effective than Imbruvica across the frontline and relapsed/refractory CLL/SLL settings.